P/E ratio for Athersys (ATHX)
P/E ratio as of April 2024 (TTM): -0.0045
According to Athersys's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.00445545. At the end of 2022 the company had a P/E ratio of -0.1286.
P/E ratio history for Athersys from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.1286 | -98.81% |
| 2021 | -10.8 | -89.62% |
| 2020 | -104 | -1.76% |
| 2019 | -106 | -46.98% |
| 2018 | -200 | 28.18% |
| 2017 | -156 | -30.65% |
| 2016 | -225 | 83.5% |
| 2015 | -123 | -13.08% |
| 2014 | -141 | 21.89% |
| 2013 | -116 | 114.01% |
| 2012 | -54.1 | -24.97% |
| 2011 | -72.1 | -29.96% |
| 2010 | -103 | -19.26% |
| 2009 | -127 | 987.74% |
| 2008 | -11.7 | 153.63% |
| 2007 | -4.62 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -232,951.90% | 🇺🇸 USA |
 Pfizer PFE | 13.7 | -306,477.58% | 🇺🇸 USA |
 Amgen AMGN | 19.1 | -428,337.33% | 🇺🇸 USA |
 Sanofi SNY | 15.5 | -347,362.34% | 🇫🇷 France |
 Merck MRK | 72.0 | -1,616,455.25% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.3 | -253,856.64% | 🇺🇸 USA |
 Moderna
MRNA | -11.8 | 265,009.02% | 🇺🇸 USA |
 Arena Pharmaceuticals
ARNA | N/A | N/A | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.